Moderna

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-01-01

Employees: 5.6K

Market Cap: $30.3B

Website: http://www.modernatx.com

Introduction: Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...

Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Phase 1

Completed

Conditions: Prevention of Chikungunya Virus Infection

Interventions: Other: Placebo
Biological: mRNA-1944

First Posted Date: 2019-02-04

Last Posted Date: 2021-07-07

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 39

Registration Number: NCT03829384

Locations: 🇺🇸
PPD Phase 1 Clinical Research Unit, Austin, Texas, United States

Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia

Phase 1

Withdrawn

Conditions: Metabolism, Inborn Errors
Methylmalonic Acidemia (MMA)

Interventions: Biological: mRNA-3704

First Posted Date: 2019-01-22

Last Posted Date: 2020-11-13

Lead Sponsor: ModernaTX, Inc.

Registration Number: NCT03810690

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

Interventions: Biological: mRNA-2752
Biological: Durvalumab

First Posted Date: 2018-11-14

Last Posted Date: 2024-05-17

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 134

Registration Number: NCT03739931

Locations: 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 21 locations

"The MaP Study": Mapping the Patient Journey in MMA and PA

Completed

Conditions: Propionic Acidemia
Methylmalonic Acidemia

First Posted Date: 2018-04-02

Last Posted Date: 2021-08-02

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 97

Registration Number: NCT03484767

Locations: 🇺🇸
Stanford Health Services, Stanford, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 14 locations

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Phase 1

Completed

Conditions: Human Metapneumovirus and Human Parainfluenza Infection

Interventions: Other: Placebo
Biological: mRNA-1653

First Posted Date: 2018-01-08

Last Posted Date: 2020-02-06

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 124

Registration Number: NCT03392389

Locations: 🇺🇸
Meridian Clinical Research, LLC, Omaha, Nebraska, United States
🇺🇸
Benchmark Research, Fort Worth, Texas, United States

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Phase 1

Completed

Conditions: Cytomegalovirus Infection

Interventions: Biological: mRNA-1647
Biological: mRNA-1443
Other: Placebo

First Posted Date: 2017-12-22

Last Posted Date: 2021-01-15

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 181

Registration Number: NCT03382405

Locations: 🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

and more 1 locations

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: VAL-339851
Other: Placebo

First Posted Date: 2017-11-17

Last Posted Date: 2021-01-11

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 156

Registration Number: NCT03345043

Locations: 🇺🇸
Miami Research Associates, Miami, Florida, United States

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

Phase 1

Completed

Conditions: Chikungunya Virus

Interventions: Other: Placebo
Biological: VAL-181388

First Posted Date: 2017-10-30

Last Posted Date: 2024-06-10

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 60

Registration Number: NCT03325075

Locations: 🇺🇸
Optimal Research, Rockville, Maryland, United States

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase 1

Terminated

Conditions: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Ovarian Cancer

Interventions: Biological: mRNA-2416
Biological: Durvalumab

First Posted Date: 2017-10-27

Last Posted Date: 2024-07-31

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 79

Registration Number: NCT03323398

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸
Northwestern Memorial Hospital, Indianapolis, Indiana, United States

and more 6 locations

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Biological: mRNA-4157
Biological: SoC Treatment
Biological: Pembrolizumab

First Posted Date: 2017-10-18

Last Posted Date: 2024-11-28

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 242

Registration Number: NCT03313778

Locations: 🇺🇸
Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺
Scientia Clinical Research Ltd, Randwick, Australia
🇯🇵
National Cancer Center Hospital, Tokyo, Japan

and more 25 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy